329 related articles for article (PubMed ID: 11691807)
1. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium.
Long H; Crean CD; Lee WH; Cummings OW; Gabig TG
Cancer Res; 2001 Nov; 61(21):7878-81. PubMed ID: 11691807
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE).
Santin AD; Bellone S; Marizzoni M; Palmieri M; Siegel ER; McKenney JK; Hennings L; Comper F; Bandiera E; Pecorelli S
Cancer; 2007 Apr; 109(7):1312-22. PubMed ID: 17326053
[TBL] [Abstract][Full Text] [Related]
3. Claudin-4-targeted therapy using Clostridium perfringens enterotoxin for prostate cancer.
Maeda T; Murata M; Chiba H; Takasawa A; Tanaka S; Kojima T; Masumori N; Tsukamoto T; Sawada N
Prostate; 2012 Mar; 72(4):351-60. PubMed ID: 21656836
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas.
Santin AD; Bellone S; Siegel ER; McKenney JK; Thomas M; Roman JJ; Burnett A; Tognon G; Bandiera E; Pecorelli S
Clin Cancer Res; 2007 Jun; 13(11):3339-46. PubMed ID: 17545541
[TBL] [Abstract][Full Text] [Related]
5. Compositional and stoichiometric analysis of Clostridium perfringens enterotoxin complexes in Caco-2 cells and claudin 4 fibroblast transfectants.
Robertson SL; Smedley JG; Singh U; Chakrabarti G; Van Itallie CM; Anderson JM; McClane BA
Cell Microbiol; 2007 Nov; 9(11):2734-55. PubMed ID: 17587331
[TBL] [Abstract][Full Text] [Related]
6. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase Cα inhibitor enhances the sensitivity of human pancreatic cancer HPAC cells to Clostridium perfringens enterotoxin via claudin-4.
Kyuno D; Kojima T; Ito T; Yamaguchi H; Tsujiwaki M; Takasawa A; Murata M; Tanaka S; Hirata K; Sawada N
Cell Tissue Res; 2011 Dec; 346(3):369-81. PubMed ID: 22160590
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
Santin AD; Cané S; Bellone S; Palmieri M; Siegel ER; Thomas M; Roman JJ; Burnett A; Cannon MJ; Pecorelli S
Cancer Res; 2005 May; 65(10):4334-42. PubMed ID: 15899825
[TBL] [Abstract][Full Text] [Related]
9. Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis.
Kominsky SL; Tyler B; Sosnowski J; Brady K; Doucet M; Nell D; Smedley JG; McClane B; Brem H; Sukumar S
Cancer Res; 2007 Sep; 67(17):7977-82. PubMed ID: 17804705
[TBL] [Abstract][Full Text] [Related]
10. Preparation of a claudin-targeting molecule using a C-terminal fragment of Clostridium perfringens enterotoxin.
Ebihara C; Kondoh M; Hasuike N; Harada M; Mizuguchi H; Horiguchi Y; Fujii M; Watanabe Y
J Pharmacol Exp Ther; 2006 Jan; 316(1):255-60. PubMed ID: 16183701
[TBL] [Abstract][Full Text] [Related]
11. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
Zhigang Z; Wenlu S
Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
[TBL] [Abstract][Full Text] [Related]
12. A novel M(r) 32,000 nuclear phosphoprotein is selectively expressed in cells competent for self-renewal.
Walensky LD; Coffey DS; Chen TH; Wu TC; Pasternack GR
Cancer Res; 1993 Oct; 53(19):4720-6. PubMed ID: 7691403
[TBL] [Abstract][Full Text] [Related]
13. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer.
Cocco E; Casagrande F; Bellone S; Richter CE; Bellone M; Todeschini P; Holmberg JC; Fu HH; Montagna MK; Mor G; Schwartz PE; Arin-Silasi D; Azoudi M; Rutherford TJ; Abu-Khalaf M; Pecorelli S; Santin AD
BMC Cancer; 2010 Jul; 10():349. PubMed ID: 20598131
[TBL] [Abstract][Full Text] [Related]
14. Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors.
Walther W; Petkov S; Kuvardina ON; Aumann J; Kobelt D; Fichtner I; Lemm M; Piontek J; Blasig IE; Stein U; Schlag PM
Gene Ther; 2012 May; 19(5):494-503. PubMed ID: 21975465
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells.
Sung SY; Kubo H; Shigemura K; Arnold RS; Logani S; Wang R; Konaka H; Nakagawa M; Mousses S; Amin M; Anderson C; Johnstone P; Petros JA; Marshall FF; Zhau HE; Chung LW
Cancer Res; 2006 Oct; 66(19):9519-26. PubMed ID: 17018608
[TBL] [Abstract][Full Text] [Related]
16. Expression of bone morphogenetic protein-7 (BMP-7) in human prostate.
Masuda H; Fukabori Y; Nakano K; Shimizu N; Yamanaka H
Prostate; 2004 Apr; 59(1):101-6. PubMed ID: 14991870
[TBL] [Abstract][Full Text] [Related]
17. Role of C-terminal regions of the C-terminal fragment of Clostridium perfringens enterotoxin in its interaction with claudin-4.
Takahashi A; Kondoh M; Masuyama A; Fujii M; Mizuguchi H; Horiguchi Y; Watanabe Y
J Control Release; 2005 Nov; 108(1):56-62. PubMed ID: 16091298
[TBL] [Abstract][Full Text] [Related]
18. Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo.
Katahira J; Sugiyama H; Inoue N; Horiguchi Y; Matsuda M; Sugimoto N
J Biol Chem; 1997 Oct; 272(42):26652-8. PubMed ID: 9334247
[TBL] [Abstract][Full Text] [Related]
19. A novel tumor-targeted therapy using a claudin-4-targeting molecule.
Saeki R; Kondoh M; Kakutani H; Tsunoda S; Mochizuki Y; Hamakubo T; Tsutsumi Y; Horiguchi Y; Yagi K
Mol Pharmacol; 2009 Oct; 76(4):918-26. PubMed ID: 19638534
[TBL] [Abstract][Full Text] [Related]
20. Role of tyrosine residues in modulation of claudin-4 by the C-terminal fragment of Clostridium perfringens enterotoxin.
Harada M; Kondoh M; Ebihara C; Takahashi A; Komiya E; Fujii M; Mizuguchi H; Tsunoda S; Horiguchi Y; Yagi K; Watanabe Y
Biochem Pharmacol; 2007 Jan; 73(2):206-14. PubMed ID: 17097620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
